Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1Phase 1 1

Status

Active not recruiting 3Completed 2Terminated 1

Sponsor Class

INDUSTRY 3NIH 2NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Thoracic 1Plasma cell 1Lymphoid 1Gynecologic 1

Conditions

Breast Neoplasms 2Ovarian Neoplasms 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Lymphoma 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 302Carboplatin 155Nivolumab 154Cisplatin 139Cyclophosphamide 130Paclitaxel 127Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 90Gemcitabine 87Dexamethasone 83Biopsy 81Ipilimumab 78Docetaxel 75Doxorubicin 75Rituximab 69Etoposide 67atezolizumab 61durvalumab 60Lenalidomide 59Radiation 59Pemetrexed 58Taxes 57Bevacizumab 54Prednisone 54fludarabine 54olaparib 53Cytarabine 49Vincristine 49Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × ipatasertib × 1 year × Clear all
NCT06400251 2026-06-01

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT03337698 2026-05-12

Morpheus Lung

Hoffmann-La Roche

Phase 1/2 Terminated
314 enrolled 31 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04650581 2026-04-13

FINER

Canadian Cancer Trials Group

Phase 3 Active not recruiting
250 enrolled 13 charts
Breast

Breast Neoplasms

NCT05276973 2025-12-19

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
25 enrolled 14 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed
529 enrolled 16 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT03280563 2025-11-10

MORPHEUS HR+BC

Hoffmann-La Roche

Phase 1/2 Completed
144 enrolled 25 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡